Mansura Akter Enni

Ms. Mansura Akter Enni

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2022 in American Journal of Advanced Technology and Engineering Solutions
Verified
Journal Article
Open access
PDF file
MEMansura Akter Enni
Mansura Akter Enni
AMAbdul Ahad Maraj
Abdul Ahad Maraj
The escalating global burden of inflammatory diseases—marked by persistent immune dysregulation, multisystem involvement, and complex molecular etiologies—has intensified the need for innovative therapeutic strategies that minimize cost, reduce development timelines, and increase success rates. Drug repurposing, the practice of identifying new therapeutic uses for existing drugs, has emerged as a strategic alternative to de novo drug discovery, particularly through in silico methodologies such as molecular docking, virtual screening, and cheminformatics-guided candidate selection. This systematic review synthesizes and evaluates recent advancements in computational repurposing approaches aimed at inflammatory disorders, including rheumatoid arthritis, inflammatory bowel disease, psoriasis, and systemic lupus erythematosus. Following the PRISMA 2020 guidelines, a comprehensive literature search was conducted across multiple scientific databases—including PubMed, Scopus, Web of Science, Embase, and IEEE Xplore—to identify peer-reviewed studies published between January 2010 and April 2022. A total of 65 articles met the inclusion criteria, encompassing diverse in silico workflows that examined drug-target interactions using molecular docking platforms such as AutoDock, AutoDock Vina, Schrödinger’s Glide, MOE, and GOLD, often combined with ADMET profiling tools (e.g., SwissADME, pkCSM) and molecular dynamics simulations to validate binding stability. Target proteins of interest commonly included pro-inflammatory mediators such as TNF-α, IL-6, IL-1β, JAK1/2, and NF-κB, with FDA-approved kinase inhibitors and anti-cancer drugs frequently emerging as high-affinity binders suitable for cross-disease application. In addition, the review documents methodological convergence in scoring thresholds, ligand library design, and reproducibility standards across computational studies. Several case studies demonstrate successful downstream validation of in silico predictions via in vitro or in vivo assays, reinforcing the translational potential of these approaches. However, key challenges persist, including lack of consensus on docking protocol standardization, limited exploration of off-target toxicities, and insufficient integration with systems pharmacology and biological network modeling. This review concludes that in silico drug repurposing represents a rapidly evolving, resource-efficient approach for identifying new treatments in immunopathology, but emphasizes the need for hybrid computational-experimental pipelines and improved benchmarking to realize its full clinical utility.

3 January 2024 in American Journal of Scholarly Research and Innovation
Verified
Journal Article
Open access
PDF file
MEMansura Akter Enni
Mansura Akter Enni
SMShaiful Mahmud
Shaiful Mahmud
BABangladesh
Bangladesh
Single nucleotide polymorphisms (SNPs) represent the most prevalent form of genetic variation in the human genome and are widely recognized for their role in influencing susceptibility to complex diseases, including type 2 diabetes mellitus (T2DM) and autoimmune disorders such as rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). Given their rich genetic heterogeneity, distinct evolutionary histories, and high burden of metabolic and immune-related diseases, South Asian populations offer a compelling landscape for exploring SNP-disease associations. However, global genomic research continues to underrepresent these populations, resulting in limited population-specific insights and potential misclassification of disease risk. This study conducted a comprehensive integrative review to synthesize existing empirical evidence on SNP polymorphism studies focused on diabetes and autoimmune disorders across South Asian countries—namely India, Bangladesh, Pakistan, Nepal, and Sri Lanka. A total of 114 peer-reviewed research articles, published between 2000 and 2024, were systematically identified, screened, and analyzed according to integrative review guidelines. The findings revealed consistent associations between several SNPs and disease phenotypes, including TCF7L2 (rs7903146), FTO (rs9939609), and SLC30A8 (rs13266634) in relation to T2DM, and HLA-DRB1, PTPN22, STAT4, and CTLA4 in the context of autoimmune diseases. While many of these loci mirrored global GWAS findings, their allele frequencies and effect sizes varied markedly across South Asian subpopulations, with notable differences between ethnic, linguistic, and caste-based groups. Despite these insights, the review identified key methodological and infrastructural gaps, including reliance on low-throughput genotyping techniques, limited sample sizes, underutilization of SNP–SNP and gene–environment interaction models, and minimal integration of functional annotation. Clinical translation remains nascent, with very few studies advancing toward the development of population-specific polygenic risk scores or diagnostic tools. Moreover, tribal, rural, and marginalized communities remain largely unrepresented in genomic research, limiting equitable knowledge generation. Ethical oversight, informed consent processes, and genomic literacy were also found to be inconsistently addressed. This review underscores the need for comprehensive, methodologically rigorous, and ethically inclusive SNP research in South Asia. Expanding genomic reference panels, investing in high-throughput technologies, and fostering collaboration across national and regional institutions will be critical for advancing precision medicine and reducing health disparities in this genetically diverse and populous region.

1 March 2025
Verified
Journal Article
Open access
PDF file
MEMansura Akter Enni
Mansura Akter Enni
BABangladesh
Bangladesh
The integration of bioinformatics in public health genomics has significantly advanced the capacity to identify, analyze, and interpret genetic variations such as single nucleotide polymorphisms (SNPs) and mutations, which play critical roles in disease susceptibility, progression, and treatment outcomes. This systematic review, conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, synthesizes the findings of 89 peer-reviewed articles published between 2010 and 2024. The review aimed to explore the evolution, application, and effectiveness of computational tools in SNP detection, variant annotation, mutation analysis, and their translational relevance in public health and clinical settings. Specifically, the review examines widely adopted variant calling tools (e.g., GATK, SAMtools, FreeBayes), annotation frameworks (e.g., ANNOVAR, SnpEff, VEP), and pathogenicity prediction algorithms (e.g., SIFT, PolyPhen-2, CADD, REVEL). It also reviews the role of genome-wide association studies (GWAS) and the increasing use of polygenic risk scores (PRS) for population-level risk stratification. A focused assessment of curated mutation databases such as ClinVar, HGMD, and OMIM underscores their role in diagnostic interpretation and clinical decision support. Additionally, population-specific SNP mapping and multi-omics integration approaches are analyzed to highlight emerging practices in understanding regulatory variants and non-coding genomic elements. The findings indicate a robust shift toward integrative, high-throughput, and standardized bioinformatics pipelines across both research and clinical domains. This review provides a consolidated perspective on the current landscape and methodological trends in bioinformatics-driven SNP and mutation analysis, offering critical insights for researchers, clinicians, and public health professionals working to leverage genomics in disease prevention, diagnosis, and precision healthcare.

1 January 2025
Verified
Journal Article
Open access
PDF file
SMShaiful Mahmud
Shaiful Mahmud
MEMansura Akter Enni
Mansura Akter Enni
Allele-Specific Polymerase Chain Reaction (AS-PCR) is a highly specific molecular technique widely employed for the detection of single nucleotide polymorphisms (SNPs) and known point mutations in genetic disease screening. This study presents a comprehensive meta-analysis to evaluate the diagnostic accuracy, clinical applicability, and global integration of AS-PCR across diverse genetic conditions, including thalassemia, cystic fibrosis, sickle cell disease, hereditary cancers, and somatic mutations. Utilizing the PRISMA 2020 framework, peer-reviewed articles published between 2000 and 2024 were systematically identified and analyzed. Eligibility criteria included empirical studies reporting sensitivity, specificity, or comparative diagnostic performance of AS-PCR against standard molecular methods. A random-effects model was used to compute pooled sensitivity, specificity, and diagnostic odds ratios, while heterogeneity and publication bias were assessed through I² statistics and funnel plot analysis. The meta-analysis revealed consistently high diagnostic performance of AS-PCR, with pooled sensitivity and specificity values exceeding 95%, confirming its utility as a frontline diagnostic tool. The findings also highlighted AS-PCR’s versatility in low-resource settings, its enhanced sensitivity in digital and microfluidic formats, and its integration into national screening and reproductive health programs. Overall, this study affirms AS-PCR’s critical role in precision diagnostics and public health genomics, particularly for targeted mutation screening and cost-sensitive healthcare environments.

3 June 2025 in Journal of Bangladesh Academy of Sciences
Verified
Journal Article
Open access
PDF file
AKAuroni Semonti Khan
Auroni Semonti Khan
MAMahmuda Akter
Mahmuda Akter
MEMansura Akter Enni
Mansura Akter Enni
SKSumaiya Farah Khan
Sumaiya Farah Khan
Cryptochrome 2 (CRY2) is one of the four proteins of the cell-autonomous molecular clock in mammals. Non-synonymous SNPs of the cry2 gene, resulting in missense variants of CRY2, were correlated with metabolic disorders, cancers, and autism spectrum disorders. This in silico analysis aimed to investigate these missense SNPs having deleterious structural and functional impacts on the human CRY2 protein. Multiple computational tools, homology modeling, and molecular dynamic simulation reported an impact on protein structural stability, function, and binding with PER2 and FBXL3. Our results suggest that missense variants of hCRY2 with L74P, L274P, L309P, F315V, and Y485H mutations were the most destabilizing. These were found to have an overall altered structure, especially in the FAD binding pocket, which in turn can impact the binding of CRY activating compounds, regulatory proteins FBXL3 and PER2. These five missense variants warrant detailed in vitro and in vivo investigations to solidify our findings. J. Bangladesh Acad. Sci. 49(1); 57-72: June 2025

12 December 2024 in Immuno
Verified
Journal Article
Open access
PDF file
Tanvir Zaman ShoyshobTanvir Zaman Shoyshob
Tanvir Zaman Shoyshob
Irin Amin HeyaIrin Amin Heya
Irin Amin Heya
NANusrat Afrin
Nusrat Afrin
MEMansura Akter Enni
Mansura Akter Enni
AJAsha Israt Jahan
Asha Israt Jahan
Md Jamal UddinMd Jamal Uddin
Md Jamal Uddin
Dengue fever is currently a major global issue, especially in tropical and subtropical countries. The absence of specific antiviral medications supports alternative dengue treatment strategies. South Asian countries have been using Carica papaya leaves as a traditional remedy for dengue for many years. Carica papaya possesses several biological features, including anti-inflammatory, antiviral, cancer-fighting, anti-diabetic, and antioxidant qualities. Additionally, numerous studies have demonstrated that bioactive compounds found in papaya leaf extracts, including carpaine, dehydrocarpaine I and II, chymopapain, and papain, significantly influence platelet counts, while phenolic compounds, such as chlorogenic acid, kaemferol, protocatechuic acid, quercetin, and 5,7-dimethoxycoumarin significantly inhibit viral replication in dengue patients, with negligible side effects. Carica papaya may be considered a viable pharmacological candidate with several targets for treating dengue. It has been shown to prevent infections, reduce oxidative stress, control cytokine storms and the immune system, lessen thrombocytopenia, and increase the body’s protein and hemoglobin levels. This literature review highlights the pathophysiological mechanism of dengue, as well as the pharmacological action of Carica papaya, both of which combat this debilitating disease. Despite these findings, additional investigation, including clinical studies, is necessary to confirm the effectiveness and safety of papaya-based treatments. It is necessary to address issues like standardizing papaya extracts, figuring out the best dosages, and assessing any drug interactions.